AVENIO ctDNA Analysis Kits are a portfolio of three NGS liquid biopsy assays for oncology research. Using a streamlined workflow to evaluate ctDNA extracted from plasma, these assays provide an end-to-end solution for tumor profiling, longitudinal monitoring of tumor burden, and minimal residual disease (MRD) detection.
A 17-gene (81kb) pan-cancer assay containing genes in NCCN guidelines and optimized for lung cancer and colorectal cancer research.
A 77-gene (192kb) pan-cancer assay containing genes in the NCCN guidelines and emerging biomarkers, and optimized for lung cancer and colorectal cancer applications.
A 197-gene (198kb) assay, containing 17 NCCN guideline-aligned genes, plus 471 frequently mutated disease-associated regions across 197-genes; optimized for longitudinal monitoring of tumor burden in lung and colorectal cancer.